

Reference:	FOI.14550.24
Subject:	Breast cancer treatments
Date of Request:	3 June 2024

Requested:

1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:

- Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide
- Aromatase Inhibitor as a single agent
- Atezolizumab
- Capecitabine as a single agent
- Carboplatin + Paclitaxel
- Eribulin as a single agent or in combination
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Palbociclib + Fulvestrant
- Parp Inhibitors (Olaparib/Talazoparib)
- Pembrolizumab
- Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)
- Ribociclib + Fulvestrant
- Sacituzumab Govitecan
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Transtuzumab deruxtecan
- Trastuzumab as a single agent or in combination
- Trastuzumab emtansine
- Any other active systemic anti-cancer therapy

2. If breast cancer is not treated at or within the Health Board, where are patients referred?

Response:

1. Hywel Dda University Health Board (UHB) provides within the table below the number of patients that have been treated for breast cancer (any stage) in the past three months with the following systemic anti-cancer therapies:

It should be noted that some of the therapies listed are recorded together on the ChemoCare system so are unable to be split; therefore, the information has been provided as recorded on the ChemoCare system.

Anti-Cancer Therapies	Number
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	28

Abemaciclib + Fulvestrant	Unable to split on ChemoCare system. See information above
Alpelisib + Fulvestrant	0
Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	*
Aromatase Inhibitor as a single agent	Not held on ChemoCare
Atezolizumab	*
Capecitabine as a single agent	12
Carboplatin + Paclitaxel	0
Eribulin as a single agent or in combination	*
Everolimus + Exemestane	0
Fulvestrant as a single agent	29
Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	32
Palbociclib + Fulvestrant	Unable to split on ChemoCare system. See information above
Parp Inhibitors (Olaparib/Talazoparib)	*
Pembrolizumab	24
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	25
Ribociclib + Fulvestrant	Unable to split on ChemoCare system. See information above
Sacituzumab Govitecan	*
Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	50
Transtuzumab deruxtecan	6
Trastuzumab as a single agent or in combination	35
Trastuzumab emtansine	9
Any other active systemic anti-cancer therapy	127

Where the figures in the table have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FOIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

2. Not applicable